Raymond James & Associates’s Encompass Health EHC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $15.5M | Buy |
160,545
+25,907
| +19% | +$2.33M | 0.01% | 958 |
|
|
2024
Q2 | $11.6M | Buy |
134,638
+9,701
| +8% | +$814K | 0.01% | 1086 |
|
|
2024
Q1 | $10.3M | Sell |
124,937
-12,539
| -9% | -$918K | 0.01% | 1140 |
|
|
2023
Q4 | $9.17M | Sell |
137,476
-27,460
| -17% | -$1.78M | 0.01% | 1157 |
|
|
2023
Q3 | $11.1M | Buy |
164,936
+8,952
| +6% | +$616K | 0.01% | 980 |
|
|
2023
Q2 | $10.6M | Sell |
155,984
-25,792
| -14% | -$1.62M | 0.01% | 1024 |
|
|
2023
Q1 | $9.83M | Buy |
181,776
+40,254
| +28% | +$2.34M | 0.01% | 1030 |
|
|
2022
Q4 | $8.46M | Sell |
141,522
-3,048
| -2% | -$166K | 0.01% | 1088 |
|
|
2022
Q3 | $6.54M | Sell |
144,570
-25,302
| -15% | -$1.27M | 0.01% | 1202 |
|
|
2022
Q2 | $7.58M | Sell |
169,872
-7,021
| -4% | -$360K | 0.01% | 1139 |
|
|
2022
Q1 | $10M | Buy |
176,893
+58,040
| +49% | +$3.03M | 0.01% | 1070 |
|
|
2021
Q4 | $6.17M | Buy |
118,853
+60,049
| +102% | +$3.1M | 0.01% | 1412 |
|
|
2021
Q3 | $3.51M | Buy |
58,804
+26,045
| +80% | +$1.64M | ﹤0.01% | 1725 |
|
|
2021
Q2 | $2.03M | Buy |
32,759
+2,047
| +7% | +$136K | ﹤0.01% | 2078 |
|
|
2021
Q1 | $2M | Buy |
30,712
+34
| +0.1% | +$2.22K | ﹤0.01% | 2015 |
|
|
2020
Q4 | $2.02M | Sell |
30,678
-721
| -2% | -$42.4K | ﹤0.01% | 1886 |
|
|
2020
Q3 | $1.62M | Buy |
31,399
+5,260
| +20% | +$270K | ﹤0.01% | 1886 |
|
|
2020
Q2 | $1.29M | Sell |
26,139
-814
| -3% | -$43.9K | ﹤0.01% | 1989 |
|
|
2020
Q1 | $1.37M | Sell |
26,953
-13,745
| -34% | -$793K | ﹤0.01% | 1786 |
|
|
2019
Q4 | $2.24M | Sell |
40,698
-476
| -1% | -$25.8K | ﹤0.01% | 1755 |
|
|
2019
Q3 | $2.07M | Sell |
41,174
-6,743
| -14% | -$339K | ﹤0.01% | 1755 |
|
|
2019
Q2 | $2.42M | Sell |
47,917
-51,014
| -52% | -$2.48M | ﹤0.01% | 1686 |
|
|
2019
Q1 | $4.6M | Sell |
98,931
-20,062
| -17% | -$1.02M | 0.01% | 1233 |
|
|
2018
Q4 | $5.84M | Buy |
118,993
+11,098
| +10% | +$631K | 0.01% | 1032 |
|
|
2018
Q3 | $6.69M | Buy |
107,895
+39,114
| +57% | +$2.38M | 0.01% | 1044 |
|
|
2018
Q2 | $3.71M | Sell |
68,781
-2,409
| -3% | -$120K | 0.01% | 1360 |
|
|
2018
Q1 | $3.24M | Sell |
71,190
-16,257
| -19% | -$697K | 0.01% | 1407 |
|
|
2017
Q4 | $3.44M | Sell |
87,447
-1,769
| -2% | -$67.3K | 0.01% | 1344 |
|
|
2017
Q3 | $3.29M | Buy |
89,216
+6,264
| +8% | +$223K | 0.01% | 1307 |
|
|
2017
Q2 | $3.19M | Sell |
82,952
-216,535
| -72% | -$7.93M | 0.01% | 1273 |
|
|
2017
Q1 | $10.2M | Buy |
299,487
+265,357
| +777% | +$8.71M | 0.02% | 666 |
|
|
2016
Q4 | $1.12M | Buy |
34,130
+4,226
| +14% | +$137K | ﹤0.01% | 1858 |
|
|
2016
Q3 | $965K | Buy |
29,904
+3,777
| +14% | +$122K | ﹤0.01% | 1909 |
|
|
2016
Q2 | $807K | Sell |
26,127
-5,410
| -17% | -$169K | ﹤0.01% | 1854 |
|
|
2016
Q1 | $944K | Buy |
31,537
+10,709
| +51% | +$296K | ﹤0.01% | 1694 |
|
|
2015
Q4 | $577K | Sell |
20,828
-4,149
| -17% | -$118K | ﹤0.01% | 1914 |
|
|
2015
Q3 | $762K | Sell |
24,977
-3,749
| -13% | -$131K | ﹤0.01% | 1740 |
|
|
2015
Q2 | $1.05M | Buy |
28,726
+6,740
| +31% | +$240K | ﹤0.01% | 1712 |
|
|
2015
Q1 | $776K | Sell |
21,986
-10,104
| -31% | -$346K | ﹤0.01% | 1808 |
|
|
2014
Q4 | $982K | Buy |
32,090
+12,857
| +67% | +$401K | ﹤0.01% | 1591 |
|
|
2014
Q3 | $565K | Sell |
19,233
-15,047
| -44% | -$459K | ﹤0.01% | 1803 |
|
|
2014
Q2 | $978K | Sell |
34,280
-2,652
| -7% | -$73.9K | 0.01% | 1509 |
|
|
2014
Q1 | $1.06M | Sell |
36,932
-86,590
| -70% | -$2.25M | 0.01% | 1382 |
|
|
2013
Q4 | $3.27M | Buy |
123,522
+20,532
| +20% | +$571K | 0.02% | 707 |
|
|
2013
Q3 | $2.83M | Buy |
102,990
+75,312
| +272% | +$1.93M | 0.02% | 713 |
|
|
2013
Q2 | $634K | Buy |
+27,678
| New | +$625K | 0.01% | 1400 |
|
Other funds holding EHC
Raymond James & Associates's EHC Position: Q3 2024 in Review
Raymond James & Associates increased its Encompass Health (EHC) stake by 19% in Q3 2024, buying an estimated $2.33M and bringing the position to 160,545 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #958.
Raymond James & Associates first reported a position in EHC in Q2 2013 and has held it in 46 quarters since. 483 funds tracked by Wall St. Rank hold EHC as of Q3 2024.
- Raymond James & Associates held 160,545 shares of Encompass Health worth $15.5M as of Q3 2024.
- Raymond James & Associates bought 25,907 Encompass Health shares in Q3 2024, an estimated $2.33M.
- Encompass Health made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #958 holding.
- Raymond James & Associates first reported a position in Encompass Health in Q2 2013 and has held it in 46 quarters since.
- 483 funds tracked by Wall St. Rank held Encompass Health as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.